替米沙坦与左旋氨氯地平治疗轻中度高血压以及对apelin-13和脂联素的影响

Teimisartan and Levamlodipine for the Treatment of Patients with Mild to Moderate Primary Hypertension and Its Influence on Apelin-13 and Adiponectin

[目的]探讨替米沙坦与左旋氨氯地平治疗轻中度高血压的临床疗效以及对血清apelin-13和脂联素（APN）的影响.[方法]将70例轻中度高血压患者随机分为替米沙坦组和左旋氨氯地平组各35例进行治疗,疗程12周,比较两组的降压效果,并检测两组的血清apelin-13和APN水平及与健康对照组比较,观察两组治疗的不良反应.[结果]第12周末, 替米沙坦组和左旋氨氯地平组的降压达标率分别为65.7%和62.9%,两组间比较无统计学差异（P＞0.05）;降压总有效率分别为80%和77.1%及两组降压幅度比较差异均无统计学意义（P＞0.05）.替米沙坦组和左旋氨氯地平组治疗前apelin-13、APN水平均明显低于健康对照组（P＜0.05）.经治疗12周后,替米沙坦组apelin-13与APN水平明显高于治疗前及左旋氨氯地平治疗后（P＜0.05）.[结论]替米沙坦和左旋氨氯地平均能有效地降低高血压患者血压水平;替米沙坦具有升高高血压患者血清apelin-13与APN水平的作用.

[Objective]To explore the clinical efficacy of telmisartan and levamlodipine for the treatment of patients with mild to moderate primary hypertension and its influence on apelin-13 and adiponectin（APN）. [Methods] Seventy pa tients with mild to moderate primary hypertension were randomly divided into telmisartan group（ n = 35） and levamlodipine group（ n =35）. The treatment lasted for 12 weeks. The antihypertensive effect was compared between two groups. Serum apelin-13 and APN in two groups were determined and compared with health controls. The adverse reactions in two groups were observed. [Results] By the end of the 12th week, the rate of reaching standard in telmisartan group and levamlodipine group were 65.7 % and 62.9 %, respectively, and there was no statistical significance between two groups（ P〉0. 05）. The total effective rate of anti-hypertension in telmisartan group and levamlodipine group were 80% and 77. 1%, respectively, and there was no statistical significance in the degree of anti-hypertension between two groups（ P 〉0.05）. Before the treatment, the levels of apelin 13 and APN in two groups were apparently lower than those in the healthy control group（ P 〈0.05）. After 12 weeks of treatment, the levels of apelin-13 and APN in telmisartan group were apparently higher than those before the treatment an in levamlodipine group after treatment（ P d0.05）. [Conclusion] Both telmisartan and levamlodipine can effectively reduce the blood pressure of patients with hypertension. Telmisartan can increase the level of apelin-13 and APN of patients with hypertension.